GENTEC Pharmaceutical Group

gentec.es

Gentec pharmaceutical group is a private Spanish company, established in 1985, with headquarters located in Barcelona.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

news image

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More

Pharma Tech

INNOVATION ZED ANNOUNCE 2022 LAUNCH OF INSULCHECK DOSE ADD-ON TECHNOLOGY FOR INSULIN PENS

Zed | November 15, 2021

news image

Innovation Zed, developer of novel diabetes management technologies headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022. "It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream o...

Read More

PHARMACY MARKET, PHARMA TECH

SANOFI AND INNATE PHARMA EXPAND COLLABORATION FOR NATURAL KILLER CELL THERAPEUTICS IN ONCOLOGY

Sanofi and Innate Pharma | December 19, 2022

news image

Innate Pharma SA and Sanofi announced an expansion of their collaboration, with Sanofi licensing a natural killer cell engager program targeting B7H3 from Innate’s ANKETTM. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to tw...

Read More

Business Insights

DERMALIQ THERAPEUTICS SIGNS USD 15 MILLION SERIES A ROUND TO ADVANCE THREE TRANSFORMATIVE DRUG THERAPIES INTO CLINICAL TRIALS

Dermaliq Therapeutics | January 18, 2022

news image

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and lic...

Read More
news image

Business Insights

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More
news image

Pharma Tech

INNOVATION ZED ANNOUNCE 2022 LAUNCH OF INSULCHECK DOSE ADD-ON TECHNOLOGY FOR INSULIN PENS

Zed | November 15, 2021

Innovation Zed, developer of novel diabetes management technologies headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022. "It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream o...

Read More
news image

PHARMACY MARKET, PHARMA TECH

SANOFI AND INNATE PHARMA EXPAND COLLABORATION FOR NATURAL KILLER CELL THERAPEUTICS IN ONCOLOGY

Sanofi and Innate Pharma | December 19, 2022

Innate Pharma SA and Sanofi announced an expansion of their collaboration, with Sanofi licensing a natural killer cell engager program targeting B7H3 from Innate’s ANKETTM. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing and commercialization. Innate and Sanofi signed a first NK cell engagers collaboration in 2016 for the generation and evaluation of up to tw...

Read More
news image

Business Insights

DERMALIQ THERAPEUTICS SIGNS USD 15 MILLION SERIES A ROUND TO ADVANCE THREE TRANSFORMATIVE DRUG THERAPIES INTO CLINICAL TRIALS

Dermaliq Therapeutics | January 18, 2022

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and lic...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us